Several studies over the last decades have demonstrated the important role of nutrition in the development of chronic diseases, such as cardiovascular disease and cancer. One dietary component that has been in the center of scientific research is red meat and processed meat (e.g., cold cuts, sausages, burgers). Burger, in particular, is one of the most popular red meat products and its consumption has increased rapidly in recent years due to the expansion of fast-food restaurants, its wide availability and its low price. However, due to its high animal fat content which is mostly saturated and high degree of processing, its nutritional value and the safety of its long-term high consumption have been questioned. The wide acceptance of burger by the general population, combined with the perception that it is a "burdensome" food for health, makes it an ideal subject for interventions aiming at modifying its nutritional value without downgrading its organoleptic characteristics and increasing its cost. Such an approach could be applied to the meat industry in order to develop innovative, functional meat analogues of high nutritional and organoleptic value, which could find acceptance by both meat-eating and vegetarian/vegan populations. Therefore, the aim of the present double-blind, randomized, crossover clinical trial is to explore the potential cardioprotective properties of "vegan burger", a novel meat analogue developed through the substitution of animal proteins and lipids with plant-based constituents using innovative technologies, against the conventional animal-based burger, in apparently healthy volunteers.
Age range
30 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from baseline in homeostasis model of assessment - insulin resistance (HOMA-IR) at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in total cholesterol at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in low-density lipoprotein (LDL) cholesterol at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in high-density lipoprotein (LDL) cholesterol at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in triglycerides at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in uric acid at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in urea at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in high sensitivity C-reactive protein (hsCRP) at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in systolic blood pressure (SBP) at 4 weeks
Timeframe: 0 (baseline) and 4 weeks
Change from baseline in diastolic blood pressure (DBP) at 4 weeks
Timeframe: 0 (baseline) and 4 weeks